Abstract: To investigate the status of adjuvant therapy in patients with early-stage human epidermal growth factor receptor 2 (HER2) positive breast cancer in China after dual HER2-targeted neoadjuvant therapy, trastuzumab plus pertuzumab, combined with cytotoxic drugs. Methods    The cases of stage Ⅰ-Ⅲ breast cancer treated at 104 hospitals in China between January 1, 2023 and December 31, 2023 were inquired by a questionnaire survey. The investigation included the number of cases, the proportion of HER2-positive breast cancer, the number of cases of HER2-positive breast cancer receiving dual HER2-targeted neoadjuvant therapy, the evaluation method and results of pathological response after neoadjuvant therapy, and adjuvant therapeutic regimen after neoadjuvant therapy. Results    A total of 104 hospitals participated in the questionnaire and provided clinicopathological data of 75 530 patients with early-stage breast cancer, and 7063 patients (40.4%) with HER2-positive breast cancer received neoadjuvant therapy with a dual HER2-targeted regimen. 4217 patients (59.7%) achieved pathologic complete response (pCR). The other 2846 patients did not achieved pCR (non-pCR). After dual HER2-targeted neoadjuvant therapy, 5658 patients (80.1%) continued dual HER2-targeted adjuvant therapy, 360 patients (5.1%) received trastuzumab adjuvant therapy, and 1045 patients (14.8%) received other drugs. There was significant difference between adjuvant targeted therapy in different ypTNM group (χ2=1730.058, P<0.001). Conclusion    ypTNM stage can provide a basis for formulating follow-up adjuvant therapy regimen for HER2-positive breast cancer patients with non-pCR after dual HER2-targeted neoadjuvant therapy.

Key words: breast cancer, human epidermal growth factor receptor 2 positive, neoadjuvant therapy, dual-targeted therapy, adjuvant therapy

摘要： 目的    调查中国早期HER2阳性乳腺癌病人接受曲妥珠单抗+帕妥珠单抗联合细胞毒药物（简称“双靶”）方案新辅助治疗后辅助治疗现状。方法    采用问卷调查方式登记了2023-01-01—2023-12-31中国104家医院经治的Ⅰ~Ⅲ期乳腺癌病例，调查内容包括收治例数、HER2阳性乳腺癌占比、HER2阳性乳腺癌接受双靶方案新辅助治疗例数、新辅助治疗病理疗效评价方法及结果、双靶新辅助治疗后辅助治疗方案选择情况。结果    全国104家医院提供了75 530例早期乳腺癌病人的临床病理资料。其中，7063例HER2阳性乳腺癌病人接受双靶方案新辅助治疗，4217例（59.7%）病人获得病理完全缓解（pCR），2846例未获得pCR（non-pCR）。双靶新辅助治疗后，5658例（80.1%）沿用双靶辅助治疗，360例（5.1%）仅接受曲妥珠单抗辅助治疗，1045例（14.8%）病人接受其他药物。辅助靶向治疗方案选择与ypTNM分期间差异有统计学意义（χ2=1730.058，P<0.001）。结论    ypTNM分期可能是HER2阳性乳腺癌双靶新辅助治疗后non-pCR病人制定后续辅助治疗方案的依据。

关键词: 乳腺癌, 人类表皮生长因子受体2阳性, 新辅助治疗, 双靶治疗, 辅助治疗